

TORRENT INVESTMENTS LIMITED
FORMERLY KNOWN AS
TORRENT INVESTMENTS
PRIVATE LIMITED

CIN: U67120GJ1985PLC007573
Website: www.torrentinvestments.com
Email: cs@torrentgroup.com

TORRENT INVESTMENTS LIMITED
(Formerly known as
Torrent Investments Private Limited)
Registered Office: "Samanvay",
600, Tapovan, Ambawadi,
Ahmedabad - 380015,
(Gujarat), India.
Phone: +91 79 26628300

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER
AND HALF YEAR ENDED SEPTEMBER 30, 2025

The Board of Directors of Torrent Investments Limited ("the Company") at its Meeting held on Tuesday, November 11, 2025, approved Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025 ("The Financial Results").

The Financial Results along with Limited Review Report issued thereon by the Joint Statutory Auditors are available on the website of NSE (www.nseindia.com) and on the Company's website at <https://torrentinvestments.com/tpl/r/invst/ti/investors>. The same can be accessed by scanning the QR code as mentioned below:



Place : Ahmedabad
Date : November 11, 2025

Note: The above information is in accordance with Regulation 52(8) & 62 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For, Torrent Investments Limited
(Formerly known as Torrent Investments Private Limited)

Samir Mehta
Chairperson
DIN: 00061903

IVALUE
IVALUE INFOSOLUTIONS LIMITED

Registered and Corporate Office: No. 903/1/1, 19th Main Road, 4th Sector, H.S.R. Layout, Bangalore - 560102, Karnataka, India. CIN: U72200KA2008PLC045995 | Website: www.ivaluegroup.com | Email: info@ivalue.co.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

In compliance with Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the board of directors of iValue Infosolutions Limited (the "Company") at their meeting held on November 11, 2025 considered, reviewed and approved the unaudited financial results for the quarter and half year ended September 30, 2025 (the "Financial Results").

The said Financial Results, along with the limited review report thereon, submitted by the auditors have been filed with the stock exchanges and are available on the websites of the stock exchanges (i.e., www.bseindia.com and www.nseindia.com) and also on the website of the Company (www.ivaluegroup.com). The same can also be accessed by scanning the following Quick Response (QR) Code from compatible devices:



For and on behalf of the Board of Directors of
iValue Infosolutions Limited
Sd/-
Sunilkumar Pillai
Chairman & Managing Director
DIN: 02226978

Place: Bangalore
Date: November 11, 2025

Adfactors 604/25

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Registered Office: 'B' Wing, Neelam Centre, 4th Floor, Hind Cycle Road, Worli, Mumbai, Maharashtra - 400 030.
Corporate Identification Number: L24390MH1976PLC019380
Tel. No.: +91 22-2439 5200/5500; Website: <http://www.jbpharma.com/>

Recommendations of the Committee of Independent Directors ("IDC") of J.B. Chemicals & Pharmaceuticals Limited ("Target Company") on the Open Offer (as defined below) made by Torrent Pharmaceuticals Limited ("Acquirer") to the Eligible Shareholders (as defined in the letter of offer dated November 6, 2025) of the Target Company, under Regulation 26(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations").

1.	Date	November 11, 2025
2.	Name of the Target Company (TC)	J.B. Chemicals & Pharmaceuticals Limited
3.	Details of the Offer pertaining to TC	Open offer for acquisition of up to 4,17,45,264 (four crore seventeen lakh forty five thousand two hundred and sixty four) fully paid-up equity shares of the Target Company, having face value of INR 1 (Indian Rupee one only) each ("Equity Shares"), representing 26.00% of the Expanded Share Capital (as defined in the letter of offer dated November 6, 2025), at a price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share ("Offer Price"), from the Eligible Shareholders of the Target Company ("Open Offer"). The public announcement dated June 29, 2025 ("PA"), the detailed public statement published on July 04, 2025 ("DPS"), the draft letter of offer dated July 11, 2025 ("DLOF"), the corrigendum to the PA, DPS and DLOF published on September 4, 2025 ("Corrigendum") and the letter of offer dated November 6, 2025 ("LOF") have been issued by NovaaOne Capital Private Limited, the manager to the Open Offer ("Manager"), on behalf of the Acquirer.
4.	Name(s) of the acquirer and PAC with the acquirer	Torrent Pharmaceuticals Limited is the Acquirer. Basis a review of the PA, DPS, DLOF, Corrigendum and the LOF issued by the Manager to the Offer on behalf of the Acquirer (together, the "Open Offer Documents"), the IDC notes that there are no persons acting in concert (PACs) with the Acquirer for the purposes of the Open Offer.
5.	Name of the Manager to the offer	NovaaOne Capital Private Limited, Address: Tower 2A, Floor 9, One World Centre, Lower Parel, Mumbai, 400013, Contact Person: Dhruv Bhatia, Tel. No.: +91-22-62466000, Email: jb_openoffer@novaane.com , SEBI Registration Number: INM000012935
6.	Members of the Committee of Independent Directors (Please indicate the chairperson of the Committee separately)	(a) Mr. Arun Duggal, Chairman. (b) Mr. Sumit Bose. (c) Mr. Ashwani Kumar Puri. (d) Ms. Richa Arora.
7.	IDC Member's relationship with the TC (Director, Equity shares owned, any other contract / relationship), if any	All the members of the IDC are independent directors on the board of directors of the Target Company. None of the IDC members hold any Equity Shares/ securities of the Target Company or have entered into any other contract/ relationship with the Target Company, except as directors on the board of directors of the Target Company and as members of the board committees.
8.	Trading in the Equity shares/ other securities of the TC by IDC Members	None of the members of the IDC have traded in any of the Equity Shares/ securities of the Target Company during the: (a) 12 (twelve) month period preceding the date of the PA; and (b) period from the date of the PA and till the date of this recommendation.
9.	IDC Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any.	None of the members of the IDC: (a) are directors on the board of directors of the Acquirer; (b) hold any equity shares or other securities of the Acquirer; and (c) have any contracts/ relationship with the Acquirer.
10.	Trading in the Equity shares/ other securities of the acquirer by IDC Members	None of the members of the IDC have traded in any of the Equity Shares/ securities of the Acquirer during the: (a) 12 (twelve) month period preceding the date of the PA; and (b) period from the date of the PA and till the date of this recommendation.
11.	Recommendation on the Open offer, as to whether the offer is fair and reasonable	The IDC has perused the Open Offer Documents and the certificate dated June 29, 2025, issued by G. K. Choksi & Co., Chartered Accountants which, <i>inter alia</i> , sets out the calculation of the Offer Price taking June 27, 2025 as the reference date (i.e. the working day prior to the date of the PA, since the PA was issued on a non-working day) as per the applicable regulations of the SEBI (SAST) Regulations. The IDC has also noted that the Offer Price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share has been determined in terms of Regulations 8(1) and 8(2) of the SEBI (SAST) Regulations being the highest of various parameters mentioned therein. Basis the above, IDC notes that the Offer Price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share has been determined by taking June 27, 2025 as the reference date (i.e. the working day prior to the date of the PA, since the PA was issued on a non-working day) in accordance with the applicable regulations of the SEBI (SAST) Regulations and accordingly, is of the opinion that the Offer Price is fair and reasonable.
12.	Summary of reasons for recommendation	The IDC has perused the Open Offer Documents and the certificate dated June 29, 2025, issued by G. K. Choksi & Co., Chartered Accountants, certifying the computation of the Offer Price and has considered the following reasons for making the recommendation in paragraph 11 above: (a) The Offer Price is higher than the negotiated price for acquisition of Equity Shares by the Acquirer under the share purchase agreements, i.e., INR 1,600 (Indian Rupees one thousand six hundred only) per Equity Share; (b) The Offer Price is equal to the volume-weighted average market price of the Equity Shares during the period of 60 (sixty) trading days immediately preceding the date of the PA (i.e., from April 1, 2025 to June 27, 2025), as traded on the National Stock Exchange of India Limited (the stock exchange with maximum volume of trading during such period), i.e., INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share; and (c) The Offer Price (being the highest price prescribed amongst the selective criteria) has been determined in accordance with Regulation 8(2) of the SEBI (SAST) Regulations. However, the members of the IDC draw attention of the Eligible Shareholders to the closing market price of the Equity Shares on the National Stock Exchange of India Limited and BSE Limited as on November 10, 2025, being INR 1,813.30 (Indian Rupees one thousand eight hundred thirteen and thirty paise only) per Equity Share and INR 1,813.40 (Indian Rupees one thousand eight hundred thirteen and forty paise only) per Equity Share, respectively, which is higher than the Offer Price. The Eligible Shareholders of the Target Company are advised to independently evaluate the Open Offer and the market performance of the Target Company's scrip and take an informed decision about tendering the Equity Shares held by them in the Open Offer. This statement of recommendation will be available on the website of the Target Company at www.jbpharma.com
13.	Disclosure of the Voting Pattern	The recommendations were unanimously approved by the members of IDC.
14.	Details of Independent Advisors, if any	AZB & Partners (legal advisors).
15.	Any other matter(s) to be highlighted	None.

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respects, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations.

For and on behalf of the Committee of Independent Directors
of J.B. Chemicals & Pharmaceuticals Limited:

Sd/-
Arun Duggal
Chairman of Committee of Independent Directors
DIN - 00024262

Place : Gurugram
Date : November 11, 2025

Adfactors 606/25

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES OF THE COMPANY ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")



(Please scan this QR Code to view the DRHP)

PUBLIC ANNOUNCEMENT

SEDEMAC
SEDEMAC MECHATRONICS LIMITED

Our Company was incorporated as 'SEDEMAC Mechatronics Private Limited' as a private limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated July 18, 2007, issued by the Registrar of Companies, Maharashtra at Mumbai. Further, our Company was converted into a public limited company pursuant to a resolution passed by our Board of Directors in their meeting held on April 29, 2024 and by our Shareholders pursuant to their resolution passed in an Extraordinary General Meeting held on June 7, 2024, upon which the name of our Company was changed to 'SEDEMAC Mechatronics Limited' and a fresh certificate of incorporation dated September 2, 2024 pursuant to such change of name was issued by the Registrar of Companies, Central Processing Centre. For details in relation to changes in the name and registered office of our Company, see "History and Certain Corporate Matters - Brief history of our Company" and "History and Certain Corporate Matters - Changes in the registered office" on page 273 of the draft red herring prospectus dated November 10, 2025 ("DRHP").

Registered and Corporate Office: Survey No. 270/1A/2, Pallod Farms, Baner Road, Baner, Baner Gaon, Haveli, Pune - 411 045 Maharashtra, India
Tel: +91 20 6715 7200; Website: www.sedemac.com; Contact person: Prasad Rajendra Chavan, Company Secretary and Compliance Officer; Email: cs@sedemac.com
Corporate Identity Number: U29253PN2007PLC246956

THE PROMOTERS OF OUR COMPANY: PROF. SHASHIKANTH SURYANARAYANAN, AMIT ARUN DIXIT, MANISH SHARMA
AND ANAYKUM AVINASH JOSHI

INITIAL PUBLIC OFFER OF UP TO 8,043,300 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF SEDEMAC MECHATRONICS LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION THROUGH AN OFFER FOR SALE OF, IN AGGREGATE, UP TO 8,043,300 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹[•] MILLION, COMPRISING OF UP TO 45,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹[•] MILLION BY PROMOTER SELLING SHAREHOLDER (AS DEFINED HEREINAFTER), UP TO 67,500 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹[•] MILLION BY PROMOTER GROUP SELLING SHAREHOLDER (AS DEFINED HEREINAFTER), UP TO 7,930,800 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹[•] MILLION BY INVESTOR SELLING SHAREHOLDERS (AS DEFINED HEREINAFTER) COLLECTIVELY THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS, THE "OFFERED SHARES") ("OFFER FOR SALE", AND SUCH INITIAL PUBLIC OFFERING, THE "OFFER"). THE OFFER INCLUDES A RESERVATION OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH (CONSTITUTING UP TO [•]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) AGGREGATING UP TO ₹ [•] MILLION FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (AS DEFINED HEREINAFTER) (THE "EMPLOYEE RESERVATION PORTION"). OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY OFFER A DISCOUNT OF UP TO [•]% (EQUIVALENT OF ₹[•] PER EQUITY SHARE) TO THE OFFER PRICE TO THE ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE [•]% AND [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.

THE FACE VALUE OF EQUITY SHARES IS ₹10 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, THE EMPLOYEE DISCOUNT AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [•], AN ENGLISH NATIONAL DAILY NEWSPAPER, ALL EDITIONS OF [•], A HINDI NATIONAL DAILY NEWSPAPER AND [•] EDITIONS OF [•], A MARATHI DAILY NEWSPAPER (MARATHI BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE AND NSE (TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs, may for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries and the Sponsor Banks, as applicable.

This Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process and is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs"), and such portion, the "QIB Portion" provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which at least one-third shall be available for allocation to domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations ("Retail Portion"), subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. Further, all potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 428 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated November 10, 2025 with the SEBI and with the Stock Exchanges on November 11, 2025. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and Stock Exchanges shall be made available to the public for comments, if any, for period of at least 21 days, from the date of publication of this public announcement, by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.sedemac.com and the websites of the BRLMs, i.e., ICICI Securities Limited, Avendus Capital Private Limited and Axis Capital Limited at www.icicisecurities.com, www.avendus.com and www.axiscapital.co.in, respectively. Our Company hereby invites the public to provide comments on the DRHP filed with SEBI and the Stock Exchanges with respect to disclosures made in the DRHP. The public are requested to send a copy of the comments to SEBI, the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned below in relation to the Offer. All comments must be received by SEBI and/or Company and/or the BRLMs and/or the Company Secretary and Compliance Officer of our Company in relation to the offer at their respective addresses mentioned below on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and Investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Investors is invited to "Risk Factors" beginning on page 35 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") and must be made solely on the basis of such RHP that shall be filed with the RoC as there may be material changes in the RHP from the DRHP.

The Equity Shares, when offered, through the RHP, are proposed to be listed on BSE and NSE. For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 273 of the DRHP. The liability of the members of the Company is limited by shares. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of the Company see "Capital Structure" on page 94 of the DRHP.

BOOK RUNNING LEAD MANAGERS			REGISTRAR TO THE OFFER
ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg Prabhadevi, Mumbai - 400 025, Maharashtra, India Tel: +91 22 6807 7100 Email: smi ipo@icicisecurities.com Investor Grievance ID: customercare@icicisecurities.com Website: www.icicisecurities.com Contact Person: Tanya Tiwari/ Nikita Chirania SEBI Registration Number: INM000011179	Avendus Capital Private Limited Platina Building, 9 th Floor 901 Plot No C-59 Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 6648 0050 Email: sedemac.ipo@avendus.com Investor Grievance ID: investorgrievance@avendus.com Website: www.avendus.com Contact Person: Sarthak Sawa / Pavan Teja Macharla SEBI Registration Number: INM000011021	Axis Capital Limited Axis House, 1 st Floor, Pandurang Budhkar Marg, Worli, Mumbai - 400 025, Maharashtra, India Tel: +91 22 4325 2183 Email: sedemac.ipo@axiscap.in Investor Grievance ID: complaints@axiscap.in Website: www.axiscapital.co.in Contact Person: Simran Gadhi/ Pratik Pednekar SEBI Registration Number: INM000012029	MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) C-101, Embassy 247, L B S Marg, Vikhroli (West) Mumbai - 400 083, Maharashtra, India Tel: +91 810 811 4949 Email: sedemac.ipo@in.mpgms.mufg.com Investor Grievance ID: sedemac.ipo@in.mpgms.mufg.com Website: www.in.mpgms.mufg.com Contact Person: Shanti Gopalkrishnan SEBI Registration Number: INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For SEDEMAC MECHATRONICS LIMITED
On behalf of the Board of Directors
Sd/-
Prasad Rajendra Chavan
Company Secretary and Compliance Officer

Place: Pune, Maharashtra
Date: November 11, 2025

SEDEMAC MECHATRONICS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated November 10, 2025 with SEBI and the Stock Exchanges on November 11, 2025. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, and is available on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, on the website of the Company at www.sedemac.com and the websites of the BRLMs, i.e., ICICI Securities Limited, Avendus Capital Private Limited and Axis Capital Limited at www.icicisecurities.com, www.avendus.com and www.axiscapital.co.in, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" beginning on page 35 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI and the Stock Exchanges, and should instead rely on their own examination of our Company and the Offer, including the risks involved, for making any investment decision.

The Equity Shares have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws.

Accordingly, the Equity Shares are being offered and sold outside of the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering in the United States.

Adfactors 601/25